Shots:
- The P-II PRISM-EXT, OLE of the PRISM3 trial evaluates CP101 vs PBO in 132 patients with recurrent CDI. Patients were enrolled in PRISM3 or directly enrolled after experiencing a CDI recurrence without prior treatment in PRISM3
- In the PRISM-EXT trial, 80.3% of participants achieved sustained clinical cure @8wks. following SoC antibiotics in PRISM-EXT & 78.8% of patients achieved sustained clinical cure @24wks., no treatment-related serious AEs were reported. The safety profile was consistent with that observed in PRISM3
- Finch already started recruitment for its P-III PRISM4 trial of CP101 for the prevention of recurrent CDI with results expected in 2023
Click here to read the full press release/ article | Ref: Finch Therapeutics | Image: Businesswire
The post Finch Reports Results of CP101 in P-II PRISM-EXT Trial for the Prevention of Recurrent C. difficile Infection first appeared on PharmaShots.
